首页> 外文OA文献 >Design of a Novel Cyclotide-Based CXCR4 Antagonist with Anti-Human Immunodeficiency Virus (HIV)-1 Activity
【2h】

Design of a Novel Cyclotide-Based CXCR4 Antagonist with Anti-Human Immunodeficiency Virus (HIV)-1 Activity

机译:具有抗人类免疫缺陷病毒(HIV)-1活性的新型基于环肽的CXCR4拮抗剂的设计

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Herein, we report for the first time the design and synthesis of a novel cyclotide able to efficiently inhibit HIV-1 viral replication by selectively targeting cytokine receptor CXCR4. This was accomplished by grafting a series of topologically modified CVX15 based peptides onto the loop 6 of cyclotide MCoTI-I. The most active compound produced in this study was a potent CXCR4 antagonist (EC(50) ≈ 20 nM) and an efficient HIV-1 cell-entry blocker (EC(50) ≈ 2 nM). This cyclotide also showed high stability in human serum, thereby providing a promising lead compound for the design of a novel type of peptide-based anticancer and anti-HIV-1 therapeutics.
机译:在此,我们首次报道了通过选择性靶向细胞因子受体CXCR4能够有效抑制HIV-1病毒复制的新型环氧化物的设计和合成。这是通过将一系列基于拓扑修饰的基于CVX15的肽接枝到环氧化物MCoTI-1的环6上来实现的。在这项研究中产生的最活跃的化合物是有效的CXCR4拮抗剂(EC(50)≈20 nM)和有效的HIV-1细胞进入阻滞剂(EC(50)≈2 nM)。该环化物在人血清中也显示出高稳定性,从而为设计新型的基于肽的抗癌和抗HIV-1治疗剂提供了有希望的先导化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号